GlassScriptPhysician profile
Luis A Gonzalez
NPI 1629016456
$3,084.88
in general payments reported to CMS, 2019-2025
23 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.70 · 2020: $70.21 · 2021: $20.18 · 2022: $372 · 2023: $1,719 · 2024: $685 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580 · Education: $19.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.20 |
| Education | $19.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $847.95 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $489.70 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $260.00 | 2023-2024 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.79 | 2022-2025 | Tradjenta, Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $229.33 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $178.15 | 2023-2024 | |
| Exact Sciences Corporation | $151.85 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $120.90 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $91.13 | 2023 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $81.25 | 2023 | Farxiga, Breztri |
| Cardiovascular Systems INC. | $70.21 | 2020 | |
| Glaxosmithkline, LLC. | $68.27 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $50.94 | 2023-2024 | Dexcom G6 Transmitter |
| Hydrofera LLC | $46.78 | 2022 | |
| Verona Pharma, INC. | $27.64 | 2025 | Ohtuvayre |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $25.54 | 2024 | Onpattro |
| Sanofi-Aventis U.S. LLC | $18.57 | 2023 | |
| Nevro Corp. | $17.88 | 2023 | Senza |
| Lundbeck LLC | $17.56 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.29 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.26 | 2024 | Quviviq |
| Medtronic, INC. | $15.12 | 2025 | Synchromedii |
| Si-Bone, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.